Holen Sie sich die Stockscreener-App
2.07
0.49%
0.010
Handel nachbörslich:
2.08
0.01
+0.48%
Schlusskurs vom Vortag:
$2.06
Offen:
$2.06
24-Stunden-Volumen:
759.06K
Relative Volume:
0.71
Marktkapitalisierung:
$224.25M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-3.9808
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
+12.50%
1M Leistung:
+32.69%
6M Leistung:
+7.25%
1J Leistung:
+76.92%
1-Tages-Spanne:
$1.95
$2.08
1-Wochen-Bereich:
$1.805
$2.10
52-Wochen-Spanne:
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Firmenname
Aclaris Therapeutics Inc
Sektor
Branche
Telefon
484-324-7933
Adresse
701 LEE ROAD, WAYNE, PA
Vergleichen Sie ACRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
2.07 | 215.58M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-05-28 | Eingeleitet | Wedbush | Outperform |
| 2025-03-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-11-19 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Eingeleitet | Evercore ISI | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-10-06 | Eingeleitet | BTIG Research | Buy |
| 2021-07-23 | Fortgesetzt | Jefferies | Buy |
| 2021-06-15 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-10-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Eingeleitet | SVB Leerink | Outperform |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-09 | Eingeleitet | Guggenheim | Buy |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Eingeleitet | Leerink Partners | Outperform |
| 2016-09-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-06-10 | Eingeleitet | Guggenheim | Buy |
| 2015-11-02 | Eingeleitet | Citigroup | Buy |
| 2015-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Aclaris Therapeutics to Present at Two Investor Conferences in September - MSN
Can Aclaris Therapeutics Inc. continue delivering strong returnsJuly 2025 Intraday Action & Weekly Setup with ROI Potential - khodrobank.com
Forecasting Aclaris Therapeutics Inc. price range with options dataTrade Entry Report & Reliable Price Action Trade Plans - Newser
Using data tools to time your Aclaris Therapeutics Inc. exitJuly 2025 Catalysts & Weekly Setup with ROI Potential - Newser
Volatility clustering patterns for Aclaris Therapeutics Inc.2025 Dividend Review & Fast Momentum Stock Entry Tips - Newser
Real time pattern detection on Aclaris Therapeutics Inc. stock2025 Institutional Moves & Detailed Earnings Play Strategies - Newser
Long term hold vs stop loss in Aclaris Therapeutics Inc.2025 Performance Recap & Free Technical Confirmation Trade Alerts - Newser
Market reaction to Aclaris Therapeutics Inc.’s recent newsEarnings Beat & Precise Buy Zone Identification - Newser
How sentiment analysis helps forecast Aclaris Therapeutics Inc.Weekly Profit Report & Growth Focused Investment Plans - Newser
Aclaris Therapeutics Inc. stock trendline breakdown2025 Winners & Losers & Verified Technical Signals - Newser
Can technical indicators confirm Aclaris Therapeutics Inc.’s reversal - Newser
Aclaris Therapeutics Inc. recovery potential after sell offQuarterly Portfolio Review & Free High Return Stock Watch Alerts - Newser
Will Aclaris Therapeutics Inc. benefit from rising consumer demandIPO Watch & Detailed Earnings Play Strategies - khodrobank.com
Earnings visualization tools for Aclaris Therapeutics Inc.2025 Institutional Moves & Weekly High Potential Alerts - Newser
What’s the recovery path for long term holders of Aclaris Therapeutics Inc.Quarterly Growth Report & Accurate Trade Setup Notifications - Newser
Is Aclaris Therapeutics Inc. a speculative investmentStop Loss & Weekly High Conviction Trade Ideas - khodrobank.com
What’s the beta of Aclaris Therapeutics Inc. stockPortfolio Update Report & Verified Short-Term Plans - khodrobank.com
Aclaris Therapeutics Taps Veteran Biotech Leader Roland Kolbeck as New Chief Scientific Officer - MSN
Developing predictive dashboards with Aclaris Therapeutics Inc. dataJuly 2025 Levels & Real-Time Buy Signal Alerts - Newser
Is Aclaris Therapeutics Inc. likely to announce a buybackJuly 2025 Recap & Reliable Breakout Stock Forecasts - khodrobank.com
Aclaris Therapeutics Inc. stock daily chart insightsGold Moves & High Yield Equity Trading Tips - Newser
Will Aclaris Therapeutics Inc. continue its uptrendTrade Entry Summary & Advanced Swing Trade Entry Plans - Newser
Aclaris Therapeutics Inc. stock momentum explained2025 Price Action Summary & Weekly Consistent Profit Watchlists - Newser
Is Aclaris Therapeutics Inc. stock ready for a breakoutInsider Buying & Real-Time Volume Analysis Alerts - Newser
Is Aclaris Therapeutics Inc. stock a falling knife or bargain buyJuly 2025 Volume & Expert Curated Trade Setup Alerts - khodrobank.com
Is Aclaris Therapeutics Inc.’s ROE strong enoughWeekly Trading Summary & Reliable Breakout Stock Forecasts - khodrobank.com
Will Aclaris Therapeutics Inc. face regulatory challengesTreasury Yields & Comprehensive Market Scan Reports - khodrobank.com
Aclaris Therapeutics Inc. stock outlook for YEAREarnings Overview Report & Real-Time Buy Zone Alerts - Newser
Momentum divergence signals in Aclaris Therapeutics Inc. chartPortfolio Performance Report & Safe Capital Growth Plans - Newser
This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year - Yahoo Finance
Is a relief rally coming for Aclaris Therapeutics Inc. holdersJuly 2025 PostEarnings & Advanced Swing Trade Entry Plans - Newser
Aclaris Therapeutics Inc. stock trend outlook and recovery pathJuly 2025 Patterns & Safe Entry Momentum Tips - Newser
How to escape a deep drawdown in Aclaris Therapeutics Inc.Quarterly Risk Review & Free Expert Approved Momentum Trade Ideas - Newser
Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aclaris Therapeutics Inc-Aktie (ACRS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):